New Delhi [India], August 14 (ANI): Medical doctors at a non-public hospital have reported an distinctive case of long-term survival in a affected person with HER2-positive metastatic gastric adenocarcinoma, demonstrating how a personalised multidisciplinary remedy technique combining focused remedy, surgical procedure, precision radiotherapy, and minimally invasive native ablative remedy can obtain extended illness management, even in advanced-stage gastric most cancers.
The affected person, a 65-year-old man, introduced with belly ache, vomiting, vital weight reduction, and metastatic illness involving the liver in 2018. Diagnostic analysis confirmed HER2-positive metastatic gastric adenocarcinoma, a extremely aggressive type of abdomen most cancers with a traditionally poor prognosis. Sufferers with metastatic gastric most cancers sometimes have a five-year survival charge of lower than 10%.
The affected person was initiated on first-line remedy with CAPOX chemotherapy (capecitabine and oxaliplatin) mixed with trastuzumab, a focused anti-HER2 remedy. The remedy resulted in a exceptional discount in each the first tumour and liver metastases, enabling the affected person to transition to long-term upkeep remedy.
Following sustained illness management, the multidisciplinary workforce carried out conversion surgical procedure, eradicating the first abdomen tumour after attaining a wonderful systemic response. Subsequent imaging confirmed full disappearance of liver lesions.
Over the next years, the affected person skilled two remoted episodes of illness development in 2021 and in 2024. As a substitute of fixing the complete systemic remedy, the treating workforce efficiently managed these recurrences utilizing extremely focused native therapies. The primary recurrence close to the surgical web site was handled with precision radiotherapy, whereas a later solitary liver lesion was efficiently managed with microwave ablation. All through this era, HER2-targeted remedy was continued, permitting the affected person to keep up wonderful high quality of life and sustained illness management.
Commenting on the case, Dr. Shyam Aggarwal, Chairman, Medical Oncology, Sir Ganga Ram Hospital, stated, ‘Systemic remedy of gastric most cancers has advanced considerably through the years. Right now, 4 key biomarkers–HER2, MSI, CPS, and Claudin 18.2–play an important function in figuring out essentially the most acceptable first-line remedy technique. The addition of focused therapies alongside chemotherapy has remodeled outcomes for a lot of sufferers with abdomen most cancers. This case highlights how precision drugs and a personalised, multidisciplinary strategy will help obtain long-term illness management, even in sufferers with superior metastatic illness.’
Roughly 15-20% of gastric cancers overexpress the HER2 protein, making them eligible for focused therapies reminiscent of trastuzumab. Advances in molecular diagnostics, imaging, and multidisciplinary most cancers care are more and more enabling clinicians to tailor remedy methods for chosen sufferers with superior illness.
This exceptional case demonstrates that sustaining HER2-directed remedy, mixed with fastidiously timed native interventions for remoted recurrences, can present sturdy medical profit far past the outcomes historically anticipated in metastatic gastric most cancers.
The medical doctors imagine that this case reinforces the significance of precision oncology and individualised remedy planning, providing renewed hope for sufferers with superior HER2-positive gastric most cancers. (ANI)
